SRZN stock icon

Surrozen
SRZN

$9.30
2.11%

Market Cap: 29.7M

 

About: Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Employees: 42

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

53% more capital invested

Capital invested by funds: $9.78M [Q4 2023] → $15M (+$5.22M) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

4.05% less ownership

Funds ownership: 50.98% [Q4 2023] → 46.93% (-4.05%) [Q1 2024]

6% less funds holding

Funds holding: 17 [Q4 2023] → 16 (-1) [Q1 2024]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 1 (-1) [Q1 2024]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for SRZN.

Financial journalist opinion